Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors
04.09.2025 - 09:30:48 | prnewswire.co.uk
Seasoned executive with three decades of experience in pharma and biotechBiotech board experience from Cytovation ASA, Antev Ltd, and Calliditas Therapeutics, and governance / senior leadership experience from UCB, Novartis and Schering-Plough (now Merck)Appointment comes as Blue Cell looks to progress its lead candidate, allogeneic stem cell treatment BlueC-231, into Phase 1/2a clinical trials for the treatment of severe erectile dysfunction (ED) following prostate cancer surgeryView original content:https://www.prnewswire.co.uk/news-releases/blue-cell-therapeutics-appoints-highly-experienced-pharma-and-biotech-executive-olav-hellebo-as-chairman-of-the-board-of-directors-302545521.html
So schätzen Börsenprofis die Aktie Blue ein. Verpasse keine Chance mehr.
Ob Chancen, Risiken oder neue Signale zur Aktie Blue: trading-notes liefert dir seit 2005 dreimal pro Woche verlässliche Aktien-Impulse zu diesem und vielen weiteren spannenden Aktien-Werten – dreimal pro Woche kostenlos per E-Mail.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
CH0038389992 | BLUE | boerse | 68162008 |

